Skip to main content
Equibles

Tetragon Partners GP Ltd

Position in AGIO — Agios Pharmaceuticals, Inc.

CIK 1515070 GRAND CAYMAN, E9
Back to AGIO Full portfolio

Position in AGIO

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$7,629,036
+$2,052,533 QoQ
Shares Held
205,579
+24.7% QoQ
Ownership
0.344%
of shares outstanding
% of Portfolio
1.24%
of 13F equity value
Holder Rank
#49
of 238 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in AGIO Over Time

Shares Held

Position Value (USD)

Derivatives in AGIO

reported options exposure · as of Jun 30, 2026
CallValue
$1,855,500
CallShares
50,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Tetragon Partners GP Ltd holds $170,564,204 across 22 Biotechnology names. AGIO ranks #12 (4.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 AUTL
Autolus Therapeutics plc
 9,500,000 $15,200,000
2 DFTX
Definium Therapeutics, Inc.
 286,990 $13,500,009
3 MBX
MBX Biosciences, Inc.
 203,543 $11,235,573
4 CLDX
Celldex Therapeutics, Inc.
 290,441 $10,807,309
5 RLAY
Relay Therapeutics, Inc.
 570,311 $10,670,518
6 ARWR
Arrowhead Pharmaceuticals, Inc.
 130,484 $10,635,750
7 PHVS
Pharvaris N.V.
 295,627 $10,222,781
8 IMVT
Immunovant, Inc.
 255,934 $9,861,137

All Filings in AGIO

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,855,500 50,000
2026-06-30 $7,629,036 205,579
2026-03-31 $5,576,503 164,839
2025-12-31 $4,410,129 162,018